We previously isolated the immunophilin FKBP12 as tives enhances the ligand activity, indicating that a specific cytoplasmic interactor of a member of the FKBP12 binding is inhibitory to the signaling pathways TGF␤ family type I receptors . FKBP12 of the TGF␤ family ligands. Overexpression of a myrisis known to mediate the immunosuppressive activities tylated FKBP12 in Mv1Lu cell specifically inhibits two of two macrolides, FK506 and rapamycin, by binding to separate pathways activated by TGF␤, and two point the macrolides and then recruiting, and thereby inactimutations on FKBP12 (G89P, I90K) abolish the inhibivating, the serine/threonine phosphatase calcineurin tory activity of FKBP12, suggesting that FKBP12 may and the serine kinase FRAP (or RAFT1), respectively, dock a cytoplasmic protein to the type I receptors to resulting in the blockage of the signaling pathways meinhibit TGF␤ family mediated signaling. diated by calcineurin or FRAP (Harding et al., 1989; Siekierka et al., 1989; Liu et al., 1991 Liu et al., , 1992 Clipstone and Crabtree, 1992; Brown et al., 1994; Sabatini et al., 1994; Introduction Brown et al., 1995; Zheng et al., 1995). Since FKBP12 is ubiquitous in virtually all mammalian cell types and The transforming growth factor ␤ (TGF␤) family consists is highly conserved from plants to mammals, its physioof many structurally related small peptides, which regulogical role is likely to be very important. late a wide range of critical cell growth and differentiaHere we provide evidence that one physiological role tion events (Moses et al., 1990; Border and Ruoslahti, of FKBP12 is to inhibit the TGF␤ family type I receptor 1992; Roberts and Sporn, 1993; Attisano et al., 1994; mediated signaling pathways, possibly by serving as a Kingsley, 1994; Massagué et al., 1994) . Two types of docking protein for a cytoplasmic inhibitor, e.g. calsingle transmembrane serine/threonine kinase recepcineurin, to the cytoplasmic domains of these receptors tors, the type I and type II, have been found to mediate the cellular effects of the TGF␤ family ligands. Molecular and thereby regulating their signaling activities. Furcharacterization of the type I and the type II receptors ther, we demonstrate that in the presence of ligand, the of the prototypical TGF␤ revealed that the two types of TGF␤ type II receptor phosphorylates the type I receptor receptors play different roles in mediating downstream within an undefined site, leading to the release of signaling. The type II receptor is a constitutively active FKBP12, which may be essential for the activation of the serine/threonine kinase receptor that can bind TGF␤ type I receptors. The serine-threonine phosphorylationindependently, but cannot signal without the type I redependent release of FKBP12, and another cytoplasmic ceptor (Wrana et al., 1992) . The type I receptor can only interactor (FNTA) (Wang et al., 1996) , suggests that TGF␤ bind to TGF␤ in the presence of the type II receptor family members signal via a novel mechanism distinct from those known to be employed by the members of the receptor tyrosine kinase family. ‡ Both contributed equally to the project, as co-first authors.
The entire cytoplasmic domain of R1 (He et al., 1993) , R4 (He et al., 1993 , Bassing et al., 1994 , or Thickvein (Tkv) (Brummel et al., 1994) was fused in frame with the DNA binding domain LexA to serve as the baits in the yeast two-hybrid screens. h, human; r, rat; Dr FKBP12, a novel cDNA isolated from a Drosophila imaginal disc library.
Results and Discussion

FKBP12 Is a Specific Interactor for Multiple Type I Receptors of the TGF␤ Family
Using a modified yeast two-hybrid system, we previously isolated the immunophilin FKBP12 as a candidate cytoplasmic interactor of one member (R1) of the type I receptor family . In order to isolate interactors specific for each of the known type I cDNA that is 66% identical to mouse FKBP12 was was then visualized by autoradiography. FKT7, bacteria T7 epitope isolated from a Drosophila imaginal disc cDNA library is tagged at the amino terminus of FKBP12 and subcloned in pCMV8.
as the only interactor for the decapentaplegic (DPP) R4, R4 pCMV6; R4K Ϫ , R4 (K230R) pCMV6; EV, pCMV6. The immunotype I receptor Thickvein (Tkv) (Brummel et al., 1994) , precipitated FKT7 and the coprecipitated R4 are indicated.
and was thus designated the Drosophila FKBP12 (Dr FKBP12) (T. W. et al., unpublished data). The results of the three screens are summarized in Table 1 . To determine whether FKBP12 also interacts with other known type I receptors, five different mammalian type I receptors (R1-R4, and ALK6) (He et al., 1993; ten Dijke et al., 1993 ten Dijke et al., , 1994 , two Drosophila type I receptors (Sax and Tkv) (Brummel et al., 1994; Xie et al., 1994) , and three mammalian type II receptors (tRII, aRII, mRII, type II receptors for TGF␤, activin, and Mü llerian inhibiting substance [MIS] , respectively) (Mathews and Vale, 1991; Lin et al., 1992; Teixeira et al., 1996) were tested for interaction with FKBP12, in the yeast two-hybrid system ( Figure 1A ). All tested type I receptors exhibited strong interaction with FKBP12, while the tested type II receptors did not, which indicates that FKBP12 is a specific interactor for all type I receptors.
FKBP12 Binds to the TGF␤ Type I Receptor in the Absence of TGF␤
To confirm the specific interaction between FKBP12 and the cytoplasmic domains of the type I receptors observed in yeast, we further tested the interaction between FKBP12 and the known functional TGF␤ type I receptor (R4) in COS cells (Figure 2 ). FKBP12 was tagged at its amino-terminus with a T7 tag, and coexpressed (Teixeira et al., 1996) . ography ( Figure 2 ). Both the wild-type and the kinase suggesting that the type II receptor-mediated phosphorylation of the type I receptor, not type I receptor autophosphorylation, is necessary for the release of FKBP12.
To test whether phosphorylation of the two threonines and three serines within the core sequence of the GS domain TTSGSGSG of the TGF␤ type I receptor is responsible for releasing FKBP12, the threonines and serines were mutated to valines and alanines, respectively (R4VVAAA). Like the wild-type R4, the R4VVAAA mutant failed to coprecipitate with FKBP12 in the presence of the wild-type type II receptor (Figure 3 , lane 6), but coprecipitated with FKBP12 in the presence of the kinase deficient type II receptor (Figure 3 , lane 5), indicating that phosphorylation of these sites is not responsible for releasing FKBP12. lung epithelial cell line (Mv1Lu); therefore, we turned to two nonfunctional derivatives of FK506, L685,818 and 15-O-desmethyl-FK520. Both bind to FKBP12 at the deficient mutant were coprecipitated with T7 tagged same site and with a similar affinity as FK506, but have FKBP12 (Figure 2 , lanes 3 and 4), indicating that the minimal cellular effects even at very high doses, because kinase activity of the type I receptor is not required for of their defect in calcineurin binding (Dumont et al., 1992 ; FKBP12 binding, as was also observed in yeast. Liu et al., 1992; Becker et al., 1993 (Massagué and Like, 1985) .
Nonfunctional Derivatives of FK506 Can
MIS-Induced Functional Responses
Little, if any ligand-bound wild-type R4 was coprecipi-
The ability of the nonfunctional FK506 derivatives to tated with T7-tagged FKBP12 (Figure 3, lane 1 (Wrana et al., 1994a) . To test whether these phosphorylation events stream events. In the mink lung epithelial cell line Mv1Lu, TGF␤ causes transcriptional activation of the plasminoare responsible for the observed release of FKBP12 from the ligand-bound R4, we replaced the wild-type gen activator inhibitor (PAI) promoter driving the luciferase reporter gene (3TP-Luc) (Wrana et al., 1992) Figure 4B , ''L685, 818''), indicating that releasing FKBP12 from the type I receptor alone is not sufficient to activate downstream pathways. This is not surprising, since the derivatives only release FKBP12, but can not induce other events known to be essential for the activation of the type I receptor, such as the type II receptor mediated GS domain phosphorylation (Wrana et al., 1994a) , and the release of the farnesyltransferase ␣ subunit (FNTA) (Wang et al., 1996) . Therefore, the FKBP12-releasing effect of the derivatives can only be detected in the presence of TGF␤. Since the release of FKBP12 is normally induced by the ligand/type I receptor binding (Figure 3) , the specific effect of releasing FKBP12 by the FK506 derivatives can be detected only if there are threshold doses of TGF␤, which are sufficient for inducing other necessary activation events but not for releasing FKBP12 completely. By adding the derivatives together with such doses of TGF␤, the derivatives would release the retained FKBP12, which may then lead to an increase of the TGF␤ specific response, if FKBP12 binding is inhibitory to the signaling activity of the type I receptor.
To find the threshold doses of TGF␤, excess FK506 derivatives were added with different doses of TGF␤ to Mv1Lu cells. No effect was detected when 1 M derivatives were added together with a maximal (250 pM) dose of TGF␤. This is as expected, since a high dose TGF␤ may completely release FKBP12. When 1 pM TGF␤ was added to Mv1Lu cells, it induced a 3-to 4-fold increase of the luciferase activity of the 3TP-Luc reporter ( Figure 4B , "TGF␤"), which is normally induced more than 100-fold by maximal dose (250 pM) of TGF␤, thus indicating a very weak activation of the signaling duct in fetal males through an active apoptotic process (Jost, 1947; Price et al., 1977; Trelstad et al., 1982) . The shown). Thus FKBP12 binding to the TGF␤ type I recepactivity of MIS in the regression of the Mü llerian ducts tor is not required for the activation of downstream sigcan be measured directly in an organ culture assay (Donaling events, suggesting that FKBP12 is not likely an nahoe et al., 1977) . In this assay, urogenital ridges containing both Wolffian and Mü llerian duct isolated from active signaling molecule. 14.5-day rat female fetuses, which have had no previous g/ml MIS, 100% were grade 3; when 500 nM drug was added together with 2 g/ml MIS, 50% of the ridges endogenous MIS exposure, are incubated with different doses of exogenous MIS. Regression of the Mü llerian were grade 3 and 50% were grade 4, while ridges treated with drugs alone were grade 0-1 (data not shown). duct is then monitored histologically and the degree of the regression graded from 0 (no regression) to 5 Therefore, increasing concentrations of L685,818 progressively enhanced the Mü llerian duct regression. Dif-(complete regression) as described (Donahoe et al., 1977) . When 1 g/ml MIS was added to the organ culferent doses of MIS were also tested with 500 nM 15-O-desmethyl-FK520 ( Figure 5C ). In the presence of ture, grade 1 regression, characterized by condensation of the mesenchymal cells surrounding a smaller and the drug, 0.25 g/ml MIS can cause grade 2 regression in more than 70% of the ridges, while 1 g/ml MIS alone irregularly shaped Mü llerian duct, was observed ( Figure  5A , top). When 1 M 15-O-desmethyl-FK520 alone was can cause grade 2 regression in only 25% of the ridges. Grade 4 regression was achieved when 2 g/ml MIS was added to the organ culture, no regression was detected ( Figure 5A, bottom) . However, when 1 M 15-O-desadded together with the drug, while the same degree of regression activity normally requires more than 5 g/ methyl-FK520 was added together with 1 g/ml of MIS, the duct was replaced by a cord of pycnotic epithelial ml MIS. These data indicate that FKBP12 also inhibits the MIScells and connective tissue (grade 4) ( Figure 5A , middle). We further tested the effect of four different doses of induced signaling pathway, and that Mü llerian duct regression induced by MIS can be significantly enhanced L685,818 on the regression activity of 2 g/ml MIS. At least five organ cultures were carried out for each tested by addition of the nonfunctional FK506 derivatives. Since FKBP12 interacts with all members of the TGF␤ dose of L685,818 alone (data not shown), or L685,818 with 2 g/ml MIS, the results of which were represented family type I receptors through two highly conserved type I receptor-specific domains (T. Wang et al., unpubby the percentage of the Mü llerian ducts ranked within each regression grade ( Figure 5B ). When treated with 2 lished data), we can anticipate that the nonfunctional FK506 derivatives can produce similar effects on other g/ml MIS alone, 50% of ridges were grade 1, and 50% were grade 2; when 50 nM L685, 818 was added together members of the TGF␤ family. These data also suggest that the nonfunctional derivatives of FK506 may have with 2 g/ml MIS, 75% were grade 2 and 25% were grade 3; when 250 nM drug was added together with 2 exciting therapeutic applications: one might use low 6B , ''control'' and ''mFE''). To rule out nonspecific toxicity resulting from overexpressing FKBP12 at the membrane, we used mFE in another TGF␤ response assay, the TGF␤-dependent suppression of a cyclin A promoter driven luciferase leased from the type I receptor upon ligand binding (Figure 3) , the myristylated FKBP12, although not free to travel into the cytoplasm, should also be dissociated can be abolished by FK506 derivatives that have the same FKBP12 binding properties as FK506 but lack the from the ligand-bound type I receptor. Therefore, the calcineurin binding domain, and thus lack functional inhibitory activity of the myristylated FKBP12 is not likely immunosuppressive activity (Dumont et al., 1992 ; Liu et mediated by its direct interaction with the type I real., 1992; Becker et al., 1993) . Based upon this observaceptor.
tion, we used the nonfunctional FK506 derivatives to An alternative mechanism for the inhibitory activity of specifically disrupt the FKBP12/type I receptor interacthe myristylated FKBP12 is suggested by overexprestion in both a TGF␤-responsive cell line, Mv1Lu, and an sion of a mutant myristylated FKBP12 (G89P, I90K) in MIS responsive organ, the fetal Mü llerian duct. By findMv1Lu cells. These mutations are known to be located ing doses of either TGF␤ or MIS that were sufficiently within the 80s loop of FKBP12 and to abolish calcineurin low to retain FKBP12, yet adequate to induce other binding without affecting either FK506 binding or activation events, a specific enhancement of TGF␤ re-FKBP12 prolyl-isomerase activity (Yang et al., 1993) . The sponses was uncovered in Mv1Lu cells, and an augmenmutant (mF(pk)E) failed to inhibit either of the TGF␤-tation of the degree of Mü llerian duct regression was dependent pathways (Figure 6 , ''mF(pk)E''). This data observed in a large number of organ culture assays. further indicates that FKBP12 may inhibit the type I reThese data revealed, for the first time, that FKBP12 ceptor by docking a cytoplasmic inhibitor, such as calbinding to the type I receptor is physiological and is cineurin, as depicted by the cartoon ( Figure 6E ). Before inhibitory to the signaling activity of the receptors. Since ligand binding, FKBP12 docks the inhibitor to the type detecting the FKBP12-releasing effect by the FK506 de-I receptor, thus preventing receptor signaling. Upon lirivatives is dependent upon the dissociation of the ligand binding, the type II receptor phosphorylates the gand-induced FKBP12 release from other activation type I receptor to release FKBP12 and with it, the associevents by using threshold dose ligand, the relatively ated inhibitor (see Figure 6E , "Control"). The overexweaker enhancement effect of the derivatives on the pressed myristylated FKBP12 competes with the endog-TGF␤-induced gene response, in comparison to the efenous FKBP12 to bind to the ligand-free type I receptor, fect on the MIS-induced Mü llerian duct regression, may and cannot be released into the cytoplasm upon ligandreflect a less successful dissociation of the ligandinduced phosphorylation of the type I receptor, due to induced FKBP12 release from the rest of the activation its anchorage to the membane, thus allowing the cytoevents. plasmic protein to inhibit the type I receptor in the presThe inhibitory activity of FKBP12 was further tested ence of ligand (see Figure 6E , "mFE"). The overexby overexpression of a myristylated FKBP12 in Mv1Lu pressed mutant FKBP12, although localized to the cells. Strong and specific inhibition of two separate membrane, fails to dock the inhibitor to the type I receppathways mediated by TGF␤ were detected. The inhibitor, either before, or after ligand binding to the type I tory activity of the myristylated FKBP12 was abolished receptor. Therefore, normal signaling activity of the type by two point mutations known to disrupt FKBP12 bind-I receptor is detected (see Figure 6E , "mF(pk)E").
ing to calcineurin, but not FKBP12 prolyl-isomerase activity (Yang et al., 1993) . Since ligand-induced type I receptor phosphorylation releases FKBP12, we thereConcluding Remarks fore can conclude that the inhibitory activity of FKBP12 is not mediated by its prolyl-isomerase activity, nor by Much is known about the growth stimulatory pathways its direct binding to the type I receptor, but more likely mediated by tyrosine kinase receptors, while little is by its ability to dock a cytoplasmic inhibitor of the type known about the growth inhibitory pathways activated I receptor. by the serine/threonine kinase receptors of the TGF␤ One candidate for such an inhibitor is calcineurin. family. The evolutionarily conserved, abundant cyto-FKBP12 is known to bind to calcineurin with high affinity plasmic protein FKBP12 is known to bind exogenous in the presence of the macrolide FK506. In the absence macrolide molecules to mediate immunosuppression; of FK506, FKBP12 has a weak but specific and functional however, its normal physiological roles remain obscure.
interaction with calcineurin in yeast (Cardenas et al., By using the yeast two-hybrid system, we identified 1994). Recently, FKBP12 was shown to recruit cal-FKBP12 as a common interactor of several cytoplasmic cineurin to the IP 3 receptor where calcineurin dephosdomains of the TGF␤ family type I serine/threonine kiphorylates specific sites on the IP 3 receptor to regulate nase receptors. Recent domain mapping studies reCa 2ϩ influx (Cameron et al., 1995) . Interestingly, FK506 vealed that two highly conserved type I receptor specific can compete with both the IP 3 receptor and the TGF␤ motifs are essential for the FKBP12/type I receptor bindtype I receptor to bind FKBP12, suggesting that similar ing (T. W. et al., unpublished data), which explains the motifs of the receptors are involved in binding to the molecular basis for the observed binding specificity for same FK506 binding site of FKBP12. The known binding all known type I receptors. Using the TGF␤ type I recepsites on FKBP12 for calcineurin and for FK506 are immetor as a model, we demonstrated coimmunoprecipitadiately adjacent to each other (Yang et al., 1993 ; Kistion of FKBP12 with the ligand-free type I receptor when singer et al., 1995) . Therefore, binding of the TGF␤ family both proteins were coexpressed in COS cells. In the type I receptors and the huge IP3 receptor to the FK506 same system, we further demonstrated that FKBP12 is binding site of FKBP12 suggests that calcineurin, if also released from the ligand-bound type I receptor, and that directly bound to FKBP12 in the receptor/FKBP12/calthe release is dependent upon type II receptor mediated cineurin complex, must be binding to sites removed phosphorylation of the type I receptor within an undefrom the FK506 binding site of FKBP12. Since calcineurin is a serine/threonine phosphatase, while type fined site. Interestingly, the receptor/FKBP12 interaction of an additional site to release FKBP12 and its docked inhibitor. Alternatively, complete activation of the type I receptor can be accomplished by using low dose TGF␤ to complete (1), and then excess nonfunctional FK506 derivatives to release FKBP12 and its associated inhibitor. Additional mechanisms involved in the direct inactivation of the inhibitor docked by FKBP12, such as phosphorylation of the inhibitor, may also be required during the normal activation of the type I receptor by high dose ligand. Once activated, the type I receptor may then phosphorylate a cytoplasmic substrate, which could be bound to the phosphorylated GS domain, or to other phosphorylated domains. The phosphorylated cytoplasmic substrate(s), together with the released and phosphorylated ␣ subunit of the farnesyltransferase (Wang et al., 1996) , are then responsible for transducing the activation signals downstream. Future studies to map the phosphorylation site(s) responsible for the release of FKBP12, to identify the substrates of the type I receptor kinase, and to dissect the signaling role of the farnesyltransferase ␣ subunit will provide important information for understanding the activation events at or downstream of the TGF␤ family type I receptors.
Experimental Procedures
Strains and Cell Lines
The yeast strain EGY48 MATa trp1 ura3 his3 LEU2::pLexAop6-LEU2, the E. coli hsdR, leuB600, trpC9830, lacD74, strA, galK, hisB436 are gifts from Dr. Roger Brent (Massachusetts General Hospital, Boston). The mink lung epithelial cell line , , Zervos et al., 1993 . Mammalian expression constructs of TGF␤ type I (He et al., 1993) and type II substrates is essential for signaling via the type I recepreceptors and their kinase deficient mutants were described pretors, one plausible mechanism for calcineurin to inhibit viously (Bassing et al., 1994) . R4VVAAA was a gift from Dr. Jeffery the type I receptor signaling activity is to dephosphory- anism. The model in Figure 7 summarizes our observations Yeast Two-Hybrid Screen on the inhibitory role of FKBP12 and our hypothesis
We used a modified version of the yeast two-hybrid system develregarding its potential link to other known events inoped by Roger Brent and his colleagues, as previously described volved in the activation of the TGF␤ type I receptor.
in detail Zervos et al., 1993 (Bassing et al., 1994; Wrana, 1994a) . In brief, cells grown to 50% confluency in 6-well plates were transiently Dumont, F.J., Staruch, M.J., Koprak, S.L., Siekierka, J.J., Lin, C.S., transfected with 1 g of either the transcriptional response reporter Harrison, R., Sewell, T., Kindt, V.M., Beattie, T.R., Wyvratt, M., and construct p3TP-lux, or cyclin A-Luc, alone, or together with 1 g of Sigal, N.H. (1992) . The immunosuppressive and toxic effects of FKmFE or mFpkE in PBJ5. Sixteen to twenty hours after transfection, 506 are mechanistically related: pharmacology of a novel antagonist cells were treated with TGF␤ in 0.2% serum medium for 24-28 hr.
of FK-506 and rapamycin. J. Exp. Med. 176, 751-760. For testing the effect of FK506 derivatives, cells were treated with Ebner, R., Chen, R.-H., Shum, L., Lawler, S., Zioncheck, T.F., Lee, the drug beginning 2 hr prior to the addition of TGF␤. Cell lysates A., Lopez, A.R, and Derynk, R. (1993) . Cloning of a type I TGF-␤ were made and luciferase activity was measured in a luminometer.
receptor and its effect on TGF-␤ binding to the type II receptor. Each assay was carried out in triplicates. Science 260, 1344 -1348 . Feng, X.-H., Filvaroff, E.H., and Derynck, R. (1995 . Transforming
